Ardelyx Inc (ARDX)
5.32
+0.04
(+0.76%)
USD |
NASDAQ |
Jul 03, 16:00
5.32
0.00 (0.00%)
After-Hours: 05:39
Ardelyx Research and Development Expense (Annual): 35.54M for Dec. 31, 2023
Research and Development Expense (Annual) Chart
Historical Research and Development Expense (Annual) Data
| Date | Value |
|---|---|
| December 31, 2023 | 35.54M |
| December 31, 2022 | 35.20M |
| December 31, 2021 | 91.14M |
| December 31, 2020 | 65.05M |
| December 31, 2019 | 71.68M |
| December 31, 2018 | 69.37M |
| Date | Value |
|---|---|
| December 31, 2017 | 75.48M |
| December 31, 2016 | 94.16M |
| December 31, 2015 | 39.88M |
| December 31, 2014 | 25.90M |
| December 31, 2013 | 28.09M |
| December 31, 2012 | 10.18M |
R&D Expense Definition
R&D expense is a line item from many companies' income statements.
Research and Development Expense (Annual) Range, Past 5 Years
35.20M
Minimum
2022
91.14M
Maximum
2021
59.72M
Average
65.05M
Median
2020
Research and Development Expense (Annual) Benchmarks
| Alnylam Pharmaceuticals Inc | 1.004B |
| Cytokinetics Inc | -- |
| Amicus Therapeutics Inc | 152.38M |
| Insmed Inc | 571.01M |
| Rigel Pharmaceuticals Inc | 24.52M |